Sign up to save your podcasts
Or
Share Treating and Managing Chronic Myeloid Leukemia (CML) in 2025: Dr. Jorge Cortes
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Treating and Managing Chronic Myeloid Leukemia (CML) in 2025: Dr. Jorge Cortes
In this episode of the Oncology Brothers podcast, we welcomed back Dr. Jorge Cortes from the Georgia Cancer Center to discuss the latest updates in the management of Chronic Myeloid Leukemia (CML).
Join us as we dive into the essential aspects of CML treatment, including:
• The importance of initial workup and bone marrow biopsy in diagnosing CML.
• Risk stratification and the selection of first-line therapies, including the latest TKIs like Asiminib and Ponatinib.
• Patient-centered decision-making and how to align treatment options with individual patient goals.
• Monitoring for response using BCR-ABL titer and the role of minimal residual disease (MRD).
• The significance of managing side effects associated with various TKIs, including cardiovascular risks and unique toxicities.
• Insights into the role of transplant in accelerated and blast phases of CML.
Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of CML treatment.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and tune in for more episodes on treatment algorithms, FDA approvals, and conference highlights.
#CML #TKIs #Asciminib #Imatinib #Pontatinib #Bosutinib #Dasatinib #Nilotinib #BCR-ABL #Hematology #OncologyBrothers #JorgeCortes
View all episodes
By Oncology Brothers
4.8
4040 ratings
In this episode of the Oncology Brothers podcast, we welcomed back Dr. Jorge Cortes from the Georgia Cancer Center to discuss the latest updates in the management of Chronic Myeloid Leukemia (CML).
Join us as we dive into the essential aspects of CML treatment, including:
• The importance of initial workup and bone marrow biopsy in diagnosing CML.
• Risk stratification and the selection of first-line therapies, including the latest TKIs like Asiminib and Ponatinib.
• Patient-centered decision-making and how to align treatment options with individual patient goals.
• Monitoring for response using BCR-ABL titer and the role of minimal residual disease (MRD).
• The significance of managing side effects associated with various TKIs, including cardiovascular risks and unique toxicities.
• Insights into the role of transplant in accelerated and blast phases of CML.
Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of CML treatment.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and tune in for more episodes on treatment algorithms, FDA approvals, and conference highlights.
#CML #TKIs #Asciminib #Imatinib #Pontatinib #Bosutinib #Dasatinib #Nilotinib #BCR-ABL #Hematology #OncologyBrothers #JorgeCortes
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
324 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
120 Listeners
ASCO Daily News
57 Listeners
Mayo Clinic Talks
295 Listeners
White Coat Investor Podcast
2,439 Listeners
The Curbsiders Internal Medicine Podcast
3,363 Listeners
Core IM | Internal Medicine Podcast
1,145 Listeners
The ONS Podcast
204 Listeners
OncoPharm
187 Listeners
ASCO Guidelines
43 Listeners
OncLive® On Air
22 Listeners
Becker’s Healthcare Podcast
189 Listeners
Oncology Today with Dr Neil Love
59 Listeners
Two Onc Docs
193 Listeners